MYRIAD GENETICS, INC. Valuation Myriad Genetics, Inc.
Equities
MYGN
US62855J1043
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.39 USD | -1.04% |
|
-16.45% | -9.63% |
| Jan. 15 | Myriad Genetics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:45 PM | |
| Jan. 15 | Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance | MT |
Company Valuation: Myriad Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,026 | 1,487 | 2,204 | 1,176 | 1,697 | 1,128 | 1,128 | - |
| Change | - | -26.58% | 48.19% | -46.65% | 44.34% | -33.54% | 0% | - |
| Enterprise Value (EV) 1 | 2,122 | 1,595 | 1,864 | 1,061 | 1,595 | 1,059 | 1,049 | 1,022 |
| Change | - | -24.84% | 16.87% | -43.09% | 50.32% | -33.62% | -0.93% | -2.55% |
| P/E ratio | 454x | -6.42x | -78.9x | -10.4x | -6.02x | -11.1x | -19.9x | -116x |
| PBR | 1.84x | 1.69x | 2.28x | 1.33x | 2.2x | 1.55x | 1.59x | 1.55x |
| PEG | - | 0x | 0.9x | -0x | -0x | 0.2x | 0.5x | 1.4x |
| Capitalization / Revenue | 2.38x | 2.67x | 3.19x | 1.73x | 2.25x | 1.34x | 1.29x | 1.17x |
| EV / Revenue | 2.49x | 2.86x | 2.7x | 1.56x | 2.12x | 1.26x | 1.2x | 1.06x |
| EV / EBITDA | 9.73x | - | 25.9x | -50.5x | -253x | 29x | 34.3x | 15.7x |
| EV / EBIT | 14.6x | -20.5x | 205x | -32.3x | -62.5x | 53.9x | 179x | 23.2x |
| EV / FCF | 28.3x | -24.7x | 11.5x | -7x | -9.16x | 353x | 117x | 42.6x |
| FCF Yield | 3.54% | -4.05% | 8.7% | -14.3% | -10.9% | 0.28% | 0.86% | 2.35% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.06 | -3.08 | -0.35 | -1.39 | -3.18 | -1.112 | -0.6225 | -0.1067 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 851.1 | 557 | 690.6 | 678.4 | 753.2 | 840.1 | 872 | 967.3 |
| EBITDA 1 | 218.2 | - | 71.9 | -21 | -6.3 | 36.47 | 30.55 | 65.03 |
| EBIT 1 | 145.2 | -77.9 | 9.1 | -32.8 | -25.5 | 19.64 | 5.871 | 44.05 |
| Net income 1 | 4.6 | - | -27.2 | -112 | -263.3 | -103.7 | -65.49 | -11.72 |
| Net Debt 1 | 96.6 | 107.8 | -339.8 | -114.9 | -102.4 | -69.42 | -79.22 | -106 |
| Reference price 2 | 27.23 | 19.78 | 27.60 | 14.51 | 19.14 | 12.39 | 12.39 | 12.39 |
| Nbr of stocks (in thousands) | 74,389 | 75,210 | 79,855 | 81,034 | 88,669 | 91,035 | 91,035 | - |
| Announcement Date | 8/13/19 | 2/23/21 | 2/24/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E ratio | EV / Sales | EV / EBITDA | Yield | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -11.14x | 1.26x | 29.02x | -.--% | 1.13B | ||
| 27.9x | 3.28x | 14.2x | +0.83% | 13.43B | ||
| 24.3x | 9.85x | 19.93x | +1.97% | 6.56B | ||
| 15.7x | 3.96x | 8.85x | - | 6.36B | ||
| 30.52x | 5.09x | 15.51x | +1.06% | 5.59B | ||
| -10.81x | 6.75x | -20.72x | -.--% | 4.53B | ||
| 17.27x | - | - | +2.96% | 3.13B | ||
| 53.06x | 8.04x | 23.61x | +0.55% | 2.52B | ||
| -10.59x | 2.36x | -9.78x | -.--% | 1.83B | ||
| Average | 15.14x | 5.08x | 10.08x | +0.92% | 5.01B | |
| Weighted average by Cap. | 20.23x | 5.22x | 10.61x | +1.05% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- MYGN Stock
- Valuation Myriad Genetics, Inc.